Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Eli Lilly (LLY) reported Q3 2026 revenue of $24.4B, up 39%, driven by Mounjaro and Zepbound. EPS rose 16% to $7.22. The company raised full-year revenue guidance to $91.0B-$92.0B and adjusted EPS guidance to $35.00-$36.00. Regulatory progress included FDA approvals for several drugs. Lilly also completed acquisitions of AtaiBeckley and Merida Biosciences.

Original reporting
Published Oct 29, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio — source image
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

Traders can update positioning based on the explicit full-year guidance raise and the breadth of FDA approvals, while monitoring how acquired IPR&D charges affect GAAP and non-GAAP EPS comparability.

02

Market read

A primary earnings-and-guidance update with explicit numerical raises and multiple FDA approvals, likely driving near-term repricing of 2026 expectations.

03

What to watch

Realized price declines (notably Zepbound and international) and the tax impact of nondeductible acquired IPR&D could limit upside if reimbursement or pricing pressure re-accelerates.

Relevance 10/10Novelty 9/10Timing: today’s earnings and guidance update (Oct. 29, 2026)

Background

Eli Lilly’s Q3 2026 release combines a major demand-driven revenue growth story (Mounjaro and Zepbound) with portfolio-wide regulatory progress and guidance increases.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Lilly reported Q3 2026 results and raised full-year revenue guidance midpoint by $5.5B, alongside FDA approvals across its portfolio.

Expected impact

Likely upward bias as the market prices in stronger 2026 demand and regulatory momentum, partially offset by higher IPR&D-driven EPS headwinds.

Evidence & confidence

The article is a primary earnings-and-guidance release with explicit numerical upgrades and new regulatory approvals, both direct drivers of near-term expectations.

Market effects

Reinforces GLP-1 and broader obesity-care demand durability and supports sentiment for large-cap pharma execution and regulatory throughput.

US FDA approval headlines can lift US-listed pharma sentiment and read-across to obesity and oncology peers.

Global revenue growth and non-US reimbursement dynamics (e.g., NRDL inclusion) highlight ongoing international scaling for metabolic and specialty franchises.

Counterpoint

EPS guidance is updated but the company also highlights large acquired IPR&D charges, which can make the earnings quality less durable than revenue growth suggests.

Key entities

  • Eli Lilly and Company

    Reported Q3 2026 financial results, raised 2026 guidance, and cited multiple FDA approvals and pipeline readouts.

  • Mounjaro

    Q3 2026 revenue grew 65% to $10.7B, driving much of the quarter’s growth.

  • Zepbound

    Q3 2026 revenue grew 48% to $5.3B, with realized price pressure partially offset by demand.

  • FDA approvals

    Included cardiovascular-risk reduction for Mounjaro, Onswik insulin approval, and oncology/hematology label expansions.

  • AtaiBeckley and Merida Biosciences

    Completed acquisitions to advance therapies in mental health and autoimmune/allergic diseases.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.